drugset / Trial / NCT05733611
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
Timeline
- Start
- 2023-06-29
- Primary completion
- 2025-08-18
- Completion
- 2025-08-18
Outcome
Outcome not reported
Stopped (Business): “Business reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | RP2 | Other / unclassified | — | Other |
| Subject | RP3 | Unknown | — | Other |